M.D., Sr. Medical Director, Oncology, Clinical Development, Idera Pharmaceuticals
Dr. Shah Rahimian serves as Idera Pharmaceutical’s Medical Director and Global Clinical Lead for Oncology. He is an experienced clinician with over 20 years of experience as a recognized leader in the biotechnology and pharmaceutical development industry. Before joining Idera, he derived critical development and regulatory paths leading to commercialization of several pharmaceutical products at Illumina, Antria, Targazyme and AstraZeneca. His achievements also include successful conduct of several early and late stage clinical trials and building strategic partnerships with healthcare facilities and world’s top 10 pharmaceutical companies. Dr. Rahimian has a Medical Doctor degree with fellowships in Internal Medicine and General Surgery.
Presentation Title and Company Description
Immunotherapy Showcase: Clinical Data: Novel Treatment for Anti-PD-1 Refractory Melanoma
Idera Pharmaceuticals is a clinical-stage patient-focused biopharmaceutical company developing novel nucleic acid therapeutic approaches for the treatment of certain cancers and rare diseases. Idera’s immunotherapy approach is based on the modulation of toll-like receptors (TLRs) while our third-generation antisense technology is designed to inhibit the production of disease-associated proteins by targeting RNA.